Loading company
Q32 Bio Inc.
QTTB · Nasdaq · ·
$9.54+3.4%Sep 29 close
- 1M
- -33.6%
- 6M
- +56.1%
- 1Y
- +358.7%
- 5Y
- -93.8%
QTTB · Nasdaq · ·
$9.54+3.4%Sep 29 close
The quarter ending December 31, 2024, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2024 | 3 months toDec 31, 2023 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$8.9M | -$9.5M | +5.72% |
| Profit per share | -$0.44 | -$0.78 | +43.59% |
| Free Cash Flow | -$6.2M | -$22.2M | +72.20% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Q32 Bio Inc. has no earnings call transcript available.
“Our progress so far this year has been transformative for Q32 Bio and our bempikibart development program. In July, we reported positive topline results from Part B of our SIGNAL-AA program, demonstrating clinically meaningful efficacy, preliminary signs of durability, and a well-tolerated safety profile in patients with severe and very severe alopecia areata. We look forward to sharing additional details from our 36-week results and initial findings from our 52-week results at an upcoming medical meeting,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata 1 , a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Q32 Bio Inc.’s Item 2.02 8-K filed August 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.